Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • gilby
    Junior Member
    • Jan 2013
    • 3

    goseq error message

    I’m a molecular biologist trying to teach myself some bioinformatics. At the moment, I’m using the goseq package to analyse differentially expressed genes in my rnaseq data set. I’m using the function nullp to calculate a probability weighting function. As my genome/geneID is not supported by goseq, I have calculated the gene lengths manually using:

    txsByGene=transcriptsBy(txdb,"gene")
    lengthData=median(width(txsByGene))

    I then input the lengthData vector into:

    pwf=nullp(genes,’bosTau6’,ensGene’,bias.data=lengthData)

    Error in nullp(genes, "bosTau6", "ensGene", "lengthData") :
    bias.data vector must have the same length as DEgenes vector!

    I check the lengths of the ‘genes’ and ‘lengthData’ vectors and they are the same i.e 24616. Any ideas why R is reporting that the 2 vectors have different lengths?

    lengthData vector:

    ENSBTAG00000000005 ENSBTAG00000000008 ENSBTAG00000000009
    89702.0 30289.0 2973.0

    ….

    genes vector:

    ENSBTAG00000000005 ENSBTAG00000000008 ENSBTAG00000000009
    0 0 0

    ….

    Thanks
  • emolinari
    Member
    • May 2013
    • 47

    #2
    hello All!
    I am desperately trying to run this GO analysis on my RNAseq data(human samples).
    I got stuck in creating a pwf file: I have -I guess- successfully created a DE matrix, with ENS id and 0/1 as identifier of diff-non diff expressed genes.
    here is the error message I encounter
    genes
    0 1
    19004 6715
    > pwf <- nullp(genes, "hg19", "ensGene")
    Loading hg19 length data...
    Error in qr.R(qrx) :
    could not find symbol "..." in environment of the generic function
    I noticed that the ENS ids in my matrix are not into double quotes...I am not sure if it really has an effect...I have just followed the manual step by step, but I am not able to figure out why is not going through (and I am newbie in all this).
    Anybody can help?!!

    Manu
    > sessionInfo()
    R version 2.15.2 (2012-10-26)
    Platform: x86_64-apple-darwin9.8.0/x86_64 (64-bit)

    locale:
    [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

    attached base packages:
    [1] stats graphics grDevices utils datasets methods base

    other attached packages:
    [1] goseq_1.10.0 geneLenDataBase_0.99.10 BiasedUrn_1.05 edgeR_3.0.8 limma_3.14.4 BiocInstaller_1.8.3

    loaded via a namespace (and not attached):
    [1] AnnotationDbi_1.20.7 Biobase_2.18.0 BiocGenerics_0.4.0 biomaRt_2.14.0 Biostrings_2.26.3 bitops_1.0-4.2 BSgenome_1.26.1
    [8] DBI_0.2-5 GenomicFeatures_1.10.2 GenomicRanges_1.10.7 grid_2.15.2 IRanges_1.16.6 lattice_0.20-15 Matrix_1.0-12
    [15] mgcv_1.7-22 nlme_3.1-108 parallel_2.15.2 RCurl_1.95-4.1 Rsamtools_1.10.2 RSQLite_0.11.2 rtracklayer_1.18.2
    [22] stats4_2.15.2 tools_2.15.2 XML_3.96-1.1 zlibbioc_1.4.0

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    18 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    32 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-09-2026, 10:04 AM
    0 responses
    43 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-08-2026, 10:08 AM
    0 responses
    29 views
    0 reactions
    Last Post SEQadmin2  
    Working...